Early (1 h) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats

Journal of the Neurological Sciences

Volumn 160, Issue 1, 1998, Pages 1-8

  Zhang, Rui Lan ^a   Chopp, Michael ^a,b   Zhang, Zheng G ^a   Divine, George ^c  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

^c Dept Biostatistic Res Epidemiol ^*  (United States)

Author keywords

Embolus; Focal cerebral ischemia; Hemorrhagic transformation; Rat; rht PA

Indexed keywords

ALTEPLASE; FIBRIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN DAMAGE, CHRONIC; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; RATS; RATS, WISTAR; RECOMBINANT FUSION PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032544586     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00155-5     Document Type: Article

References (32)

1. Anderson JL, Karagounis L, Allen A, Bradford MJ, Menlove RL, Pryor TA. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991;15(68):166-70.
2. del Zoppo G.J., Copeland B.R., Anderchek K., Hacke W., Koziol J.A. Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction. Stroke. 21:1990;596-601.
3. del Zoppo G.J., Poeck K., Pessin M.S., Wolpert S.M., Furlan A.J., Ferbert A., Alberts M., Zivin J., Wechsler L., Busse O., Greenlee R.J., Brass L., Mohr J.P., Feldmann E., Hacke W., Kase C.S., Biller J., Gress D., Otis S.M. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 32:1992;78-86.
4. Hacke W., Kaste M., Fieschi C., Toni D., Lesaffre E., von Kummer R., Boysen G., Bluhmki E., Hoxter G., Mahagne M.-H., Hennerici M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study. J Am Med Assoc. 274:1995;1017-1025.
5. Hacke W., Schwab S., Horn M., Spranger M., De Georgia M., von Kummer R. 'Malignant' middle cerebral artery territory infarction: clinical course and prognostic signs. Arch Neurol. 53(4):1996;309-315.
6. Hamann G.F., Okada Y., del Zoppo G.J. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 16:1996;1373-1378.
7. Hamilton M.G., Lee J.S., Cummings P.J., Zabramski J.M. A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits. Stroke. 25:1994;651-656.
8. Heiss W.D., Graf R., Lottgen J., Ohta K., Fujita T., Wagner R., Grond M., Weinhard K. Repeat positron emission tomographic studies in transient middle cerebral artery occlusion in cats: residual perfusion and efficacy of postischemic reperfusion. J Cereb Blood Flow Metab. 17:1997;388-400.
9. Jiang N., Zhang R.L., Chen H., Chopp M. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient (2 h) but not after permanent MCA occlusion in the rat. Neurosci Res Comm. 15:1994;85-93.
10. Jiang Q., Zhang R.L., Zhang Z.G., Ewing J.R., Jiang P., Chopp M. Evaluation of cerebral artery embolic stroke and rt-PA intervention using diffusion, perfusion and T2 weighted NMR imaging in rat. J Cereb Blood Flow Metab. 17:1997;S326.
11. Jorgensen L., Torvik A. Ischaemic cerebrovascular diseases in an autopsy series. 2. Prevalence, location, pathogenesis, and clinical course of cerebral infarcts. J Neurol Sci. 9:1969;285-320.
12. Larrue V., von Kummer R., del Zoppo G., Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 28:1997;957-960.
13. Levy D.E., Brott T.G., Haley E.C. Jr., Marler J.R., Sheppard G.L., Barsan W., Broderick J.P. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 25:1994;291-297.
14. Lyden P.D., Zivin J.A. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 5:1993;1-16.
15. Lyden P.D., Zivin J.A., Soll M., Sitzer M., Rothrock J.F., Alksne J. Intracerebral hemorrhage after experimental embolic infarction. Arch Neuro. 44:1987;848-850.
16. Morikawa E., Moskowitz M.A., Huang Z., Yoshida T., Irikura K., Dalkara T. L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke. 25:1994;429-435.
17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
18. Overgaard K., Sereghy T., Boysen G., Pedersen H. Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model. Scand J Clin Invest. 53:1993;383-393.
19. Overgaard K., Sereghy T., Boysen G., Pedersen H., Hoyer S., Diemer N.H. A rat model of reproducible cerebral infarction using thrombotic blood clot emboli. J Cereb Blood Flow Metab. 12:1992;484-490.
20. Overgaard K., Sereghy T., Pedersen H., Boysen G. Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model. J Cereb Blood Flow Metab. 14:1994;472-477.
21. Papadopoulos S.M., Chandler W.F., Salamat M.S., Topol E.J., Sackellarees J.C. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 67:1987;394-398.
22. Penar P.L., Greer C.A. The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia. Yale J Biol Med. 60:1987;233-243.
23. Phillips D.A., Fisher M., Smith T.W., Davis M.A. The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model. Ann Neurol. 23:1988;391-394.
24. Ringelstein E.B., Biniek R., Weiller C., Ammeling B., Nolte P.N., Thron A. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology. 42:1992;289-298.
25. Saku Y., Choki J., Waki R., Masuda J., Tamaki K., Fujishima M., Ogata J. Hemorrhagic infarct induced by arterial hypertension in cat brain following middle cerebral artery occlusion. Stroke. 21:1990;589-595.
26. Slivka A., Pulsinelli W. Hemorrhagic complications of thrombolytic therapy in experimental stroke. Stroke. 18:1987;1148-1156.
27. Swanson R.A., Morton M.T., Tsao-Wu G., Savalos R.A., Davidson C., Sharp F.R. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 10:1990;290-293.
28. Thomas G.R., Thibodeaux H., Errett C.J., Badillo J.M., Keyt B.A., Refino C.J., Zivin J.A., Bennett W.F. A long half-life and fibrin specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke. 25:1994;2072-2078.
29. Zea Longa Z., Weinstein P.R., Carlson S., Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 20:1989;84-91.
30. Zhang R.L., Chopp M., Zhang Z.G., Jiang Q. A rat model of focal embolic cerebral ischemia. Brain Res. 766:1997;83-92.
31. Zivin J.A., Fisher M., DeGirolami U., Hemenway C.C., Stashak J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science. 230:1985;1289-1292.
32. Zivin J.A., Lyden P.D., DeGirolami U., Kochhar A., Mazzarella V., Hemenway C.C., Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol. 45:1988;387-391.